abstinence violation effect, 668–669
abuse meaning of the term, 36 See also substance abuse, 43
acamprosate, 100, 139, 244, 375, 635
acetaldehyde aversive effects of, 201–202
acetylcholine, 100, 103
acetylcholine genes associations with SUDs, 200–201
acetylcholine receptors, 105 role in development of nicotine tolerance, 395–396
Acomplia, 316
Adderall, 9, 486, 489, 493
nonmedical use, 507–508
addict use of the term, 36
addiction biological basis of, 122–123 compulsive behaviors, 10–11 concurrent use of two or more drugs, 410–411 definition, 10 differences in vulnerability to, 13
DSM-5 usage, 42
essential features (American Society of Addiction Medicine), 71
meaning of the term, 36
physiological or psychological view of, 10–11
process addictions, 10–11
revised diagnostic criteria, 504–506
significance of a withdrawal syndrome, 10–11
stages and essential features, 124–125
vignette (“Sally Quits Using Cocaine ... Until She Starts Again”), 121–122 vulnerability related to dopamine D2 receptor density, 133–134
addiction medicine, 75
Addiction Severity Index, 37 for adolescents, 62 for adults, 62
addiction stages, 124–125
stage 1 (reinforcing effects of addictive drugs), 125–129
stage 2 (shift from pleasurable to dysphoric effects), 130–134
stage 3 (compulsive drug-seeking), 135–143
stage 4 (lingering vulnerability to relapse), 144–152
addictive behavior nonbiological influences on, 216 progression of, 248–251 variety of pathways into addiction, 217
addictive lifestyle, 11–13, 529 risks related opioid drug use, 563
addictive personality concept, 270–271
ADH1B gene, 201
Adolescent Drug Involvement Scale (ADIS), 57
cannabis use, 466–469 childhood stress and, 295–296
conduct disorder risk factor, 293
early indicators of SUD, 292–296
hazards of, 290–292
low socioeconomic status risk factor, 296
Monitoring the Future survey, 287–288, 291
neurobehavior disinhibition and, 293–294
parenting practices and, 295–296
peer associations and influences, 294
psychopathology risk factor, 293
reported levels of drug consumption, 287–288
risk factors for SUD, 289–290, 292–296
adolescent smoking, 414–417 consequences of, 415–416
electronic cigarettes, 415
prevalence of, 415
risk factors for, 416–417
adoption studies

© in this web service Cambridge University Press
www.cambridge.org
alcohol
adolescent alcohol abuse, 291–292
alcohol content of alcoholic beverages, 310
alcohol myopia, 320–321
anxiolytic effect, 320
as a drug, 36
behavioral effects, 318–330
binge drinking, 50, 322–323
bioavailability, 310–313
blackouts (amnesic episodes) caused by, 324–326
calories in alcoholic beverages, 310
cognitive effects, 318–330
cosmetic effects, 318–330
context effects, 331–332
cultural attitudes about, 307
disinhibition of behavior, 320–321
dose-related effects, 319
effects at increasing blood alcohol concentration (BAC), 319
effects of combination with other addictive drugs, 333–336
cost effects, 318–330
context effects, 331–332
cultural attitudes about, 307
disinhibition of behavior, 320–321
dose-related effects, 319
effects at increasing blood alcohol concentration (BAC), 319
effects of combination with other drugs, 329–330
effects on amino acid neurotransmitters, 313–315
effects on dopamine function, 315
effects on endocannabinoids, 316
effects on endogenous opioids, 316
effects on GABA activity, 100
effects on GABA function, 313–315
effects on glutamate function, 313–315
effects on neurotransmitters and brain function, 313–317
effects on serotonin function, 315
effects on sexual activity, 321–322
enduring cognitive effects of “social” drinking, 326–327
expectancy effects, 331–333
factors affecting blood alcohol concentration (BAC), 311–313
hangover, 330
hormonal stress response, 317
impaired cognition and dangerous behavior, 323–324
lethal overdose, 329–330
low potency compared with other drugs, 311
low-risk levels of consumption, 50
memory impairment, 324–326
negative emotional effects, 327–328
neuroadaptation, 317
pharmacodynamics, 313–317
pharmacokinetics, 311–313
popularity of, 307
prevalence and levels of alcohol consumption, 308–309
prevalence of use and SUDs, 8–9
problematic alcohol use, 309–310
receptor binding, 108
rewarding effects, 319–322
suicide risk, 327–328
teratogenic effects, 372–374
tolerance, 319
unfavorable and dangerous effects, 322–330
US government attempts to suppress consumption, 309
use of alcoholic beverages, 310–311
varied consequences of drinking, 318
vignette (“Selling the Proposal”), 306–307
withdrawal syndrome, 110, 317
alcohol dehydrogenase (ADH), 201–202
Alcohol Expectancy Questionnaire (AEQ), 236
alcohol metabolism aversive effects of acetaldehyde, 201–202
enzymes involved in, 201–202
genes that control it, 201–202
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), 57
alcohol use disorders
adoptive studies, 170–172
advanced stage of alcohol addiction, 349–350
age-related vulnerability to neurological damage, 369–370
alcoholic dementia, 365
Babor classification system, 353–357
behavioral impairment, 364–365
binary classification systems, 353–357
brain damage related to, 364–370
brain injury types and locations, 365–366
cardiovascular disease associated with, 371
classification systems, 353–357
Cloninger classification system, 353–357
COGA study, 197–198
co-morbidity, 384–385
cognitive impairment, 364–365
cultural influences and vulnerabilities for women, 359–360
delirium tremens stage of alcohol withdrawal, 363–364
development of, 346–352
differential heritability, 174
DSM-5 diagnostic criteria, 44–45
emotional and other costs of, 349–350
endophenotypes for, 196
fetal alcohol spectrum disorder, 372–374
genred differences in incidence, 357
Index

alcohol use disorders (cont.)
gender-related risk factors, 359–360
gender-specific differences, 358–359
immune system compromise, 370–371
in women, 357–361
incidence of, 344–346
Jellinek’s gamma-delta classification system, 353
Korsakoff’s syndrome, 364–365, 370
lifespan course of, 350–352
liver disease (including cirrhosis), 371
lower response to alcohol and SUD risk, 183–184
malnutrition and, 369–374
measuring severity, 343–344
mechanisms of neurotoxicity, 366–369
medical problems from chronic alcohol consumption, 362–374
negative consequences expressed in popular culture, 341–342
patterns and consequences for women, 361
recovery from cognitive impairment, 370
research on, 341–342
risk factors for, 346–347
special features in women, 357–361
suicide risk, 350, 361
thiamine deficiency and, 369–374
transition from benign use into use disorder, 347–349
treatment medications, 375–376
twin studies, 173–174
Type 2 alcoholism, 238
types of, 353–357
use of the terms alcoholism and alcoholic, 343
variations among, 342–344
viewed as a single disorder, 342–343
vignette (“The AA Meeting”), 341
Wernicke-Korsakoff syndrome, 364–365
withdrawal syndrome, 362–364
Alcohol Use Disorders Test (AUDIT), 57, 59
alcoholic use of the term, 36, 343
Alcoholics Anonymous (AA), 11, 22, 136, 244, 309, 325, 343, 627, 645–650, 675
alcoholism as a single disorder, 343
basic principles, 645–647
beneficial features, 647–649
evidence of effectiveness, 650
founding and influence of, 74–75
informal diagnosis of SUDs, 37
mutual help approach, 628–629
objections and limitations, 649–650
risk factors for relapse, 149–150
role of narcissism in addiction, 274–275
spirituality of, 645–647
terminology used by, 36
twelve steps of, 646–647
alcoholism use of the term, 343
See also alcohol use disorders
aldehyde dehydrogenase (ALDH), 201–202
ALDH2 gene, 202
alleles, 192
allostasis, 132–133
alprazolam, 100, 108, 262, 603, 606, 612
withdrawal syndrome, 114, 115
Alzheimer’s disease, 103, 365
Ambien, 486, 613
American Academy of Pain Medicine, 579
American Cancer Society, 343
American Academy of Sleep Medicine, 579
American Counseling Association, 334
American Lung Association, 430
American Medical Association
alcoholism as a disease, 75
cognition of addiction medicine specialty, 75
American Pain Society, 578
American Psychiatric Association (APA), 9
See also Diagnostic and Statistical Manual of Mental Disorders (DSM)
American Psychological Association, 25
American Society of Addiction Medicine, 478, 578
esential features of addiction, 71
amino acid neurotransmitters, 100
effects of alcohol, 311–315
amphetamine mechanism of action, 107
d-amphetamine, 9
amphetamine use
acute effects, 496–503
animal self-administration studies, 498–499
armed forces, 488, 496–497
behavioral effects, 496–498
bioavailability, 493–494
effects of injecting, 502–503
incentive to escalate, 503
history of, 487–493
effects on brain function, 494–496
effects on neurotransmitters, 99, 494–496
euphoric “rush” followed by aversive dysphoria, 502–503
history of, 487–493
incentive to escalate, 503
malnutrition and, 369–374
malnutrition and, 363
medical problems from chronic alcohol consumption, 362–374
nutritional and, 369–374
recovery from cognitive impairment, 370
research on, 344–346
risk factors for, 346–347
special features in women, 357–361
suicide risk, 350, 361
thiamine deficiency and, 369–374
transition from benign use into use disorder, 347–349
treatment medications, 375–376
unique features of, 366–369
variations among, 342–344
viewed as a single disorder, 342–343
vignette (“The AA Meeting”), 341
Wernicke-Korsakoff syndrome, 364–365
withdrawal syndrome, 362–364
American Psychiatric Association (APA), 9
See also Diagnostic and Statistical Manual of Mental Disorders (DSM)
American Psychological Association, 25
American Society of Addiction Medicine, 478, 578
essential features of addiction, 71
amino acid neurotransmitters, 100
effects of alcohol, 311–315
amphetamine mechanism of action, 107
d-amphetamine, 9
amphetamine use
acute effects, 496–503
animal self-administration studies, 498–499
armed forces, 488, 496–497
behavioral effects, 496–498
bioavailability, 493–494
effects of injecting, 502–503
incentive to escalate, 503
history of, 487–493
incentive to escalate, 503
malnutrition and, 369–374
malnutrition and, 363
medical problems from chronic alcohol consumption, 362–374
nutritional and, 369–374
recovery from cognitive impairment, 370
research on, 344–346
risk factors for, 346–347
special features in women, 357–361
suicide risk, 350, 361
thiamine deficiency and, 369–374
transition from benign use into use disorder, 347–349
treatment medications, 375–376
unique features of, 366–369
variations among, 342–344
viewed as a single disorder, 342–343
vignette (“The AA Meeting”), 341
Wernicke-Korsakoff syndrome, 364–365
withdrawal syndrome, 362–364
vignette ("The Pharmacist Dispenses Drugs"), 486
weight loss, 489
amphetamine use disorders, 503–512
addiction development and progression, 508–512
amphetamine use binges, 509–510
concurrent use of other addictive drugs, 509
dangers of intravenous injection, 510–512
development of tolerance, 509
harm to organ systems and biological function, 524–525
nonmedical use of pharmaceutical stimulants, 507–508
prevalence of addiction among users, 504–506
risk factors for problematic use, 506–507
routes into addiction, 508–509
amygdala, 126, 127, 134, 139, 150
extended amygdala, 151
significance of size (volume), 23, 186
analgesia
effects of opioid drugs, 554–555, 557–558
anandamide, 100, 105, 316, 447, 448–449
Anderson, Dwight, 74
aneedotal accounts of drug addiction, 14–16
angel dust. See phencyclidine
animal models of addiction, 25–26
animal studies
genomic difference and SUDs, 204–208
inbred mice and quantitative trait loci (QTLs), 205–206
knockdown mouse strains, 206
knockout (KO) mouse strains, 206–208
mutant mice, 206–208
selective breeding of experimental animals, 205
transgenic (TG) mouse strains, 206–208
ANKFNI gene, 204
Antabuse, 89, 375–376, 635
antagonist drug action, 106–108
antisocial personality disorder, 12, 81, 177–178, 182, 201, 238, 259, 270, 293, 294, 348
co-occurrence with borderline personality disorder, 274
coc-occurrence with SUDs, 53, 271–273
anxiety disorders, 178–179
coc-occurrence with SUDs, 53–54, 264–267
difficulty of nicotine withdrawal, 404
drug treatment since 1900, 596–597
prevalence of smoking in people with, 407–409
self-medication, 264–267
types of anxiolytic drugs, 595
use of SSRI antidepressant drugs, 596
anxiolytic drugs, 48, 100
alcohol, 320
misuse of, 597–598
types of, 595
withdrawal syndrome, 114
Ativan, 603
arm forces
use of amphetamine, 488, 496–497
associative learning, 218
Ativan, 603
attention-deficit hyperactivity disorder (ADHD), 116, 182, 199, 283, 293, 373, 521
drug treatments, 489
genetic factors, 193
autoreceptors, 105
inhibitory feedback function, 109
availability of addictive drugs, 246
aversive consequences of drug use, 226–228
aversive effects of high drug doses, 134
avoidant personality disorder, 275
Babor, T.F.
classification of alcohol use disorders, 353–357
baclofen, 244
Baker, Chet, 545
Bandura, Albert, 232, 245
barbiturates, 100, 262, 595, 596, 598–601
acute effects, 600
bioavailability, 599–600
effects on brain function, 599
misuse and use disorders, 600–601
pharmacodynamics, 599
pharmacokinetics, 599–600
risk of fatal overdose, 600
tolerance, 601
treatment of use disorders, 617
withdrawal syndrome, 601
Baudelaire, Charles, 455
Bechara, Antoine, 140
Beck Depression Inventory, 528
bed nucleus of the stria terminalis (BNST), 127, 150, 151
Begleiter, Henri, 24, 181–182, 198
behavior
interaction with gene expression, 195–196
modeling of, 245–246
behavior and SUDs
use of endophenotypes, 196–197
behavioral genetics, 28
complexity of, 191–193
behavioral inhibition
impairment in addiction, 139–143
behavioral neuroscience, 28
behavioral pharmacology, 25, 219, 249
behavioral phenotypes, 192
behavioral research (classic Skinnerian), 29
behavioral sensitization, 136–137, 154
long-term sensitization, 154
Index

behavioral theory of SUD, 218–232
associative learning, 218
aversive consequences of drug use, 226–228
consequences of behavior, 219
consequences of drug use, 218–228
negative reinforcement, 225–226
positive reinforcement, 219–225
progression of SUD, 248–251
reinforcement principle, 219
role of learning in behavioral flexibility, 218–219
stimulus control of SUD, 228–232
vignette (“The Power of an Immediate Reward”), 215
behavioral tolerance, 110, 215
Belushi, John, 546
Benowitz, N.L., 383, 395, 396–397–399, 413, 421, 426, 427, 430
Benzedrine, 488
benzodiazepine receptor agonists (BZRAs), 596–597, 612–617
abuse potential, 614–615
adverse effects, 616–617
bioavailability, 613–614
effects on brain function, 614
pharmacodynamics, 614
pharmacokinetics, 613–614
withdrawal syndrome, 615–616
benzodiazepines, 9, 48, 100, 262, 314, 333, 595, 596–597, 601–612
acute effects, 606–607
anterograde amnesia, 605
bioavailability, 605–606
concurrent use with other additive drugs, 609–611
drug-facilitated sexual assault, 606–607
effects on brain function, 603–605
misuse and use disorder, 607–612
pharmacodynamics, 603–605
pharmacokinetics, 605–606
treatment of use disorders, 617
types of, 602–603
withdrawal syndrome, 611–612
Berridge, K.C., 220
beta-endorphin, 100, 184
bioavailability of a drug factors affecting, 111
biological factors and SUDs, 123
addiction stage 1 (reinforcing effects of addictive drugs), 125–129
addiction stage 2 (shift from pleasurable to dysphoric effects), 130–134
addiction stage 3 (compulsive drug-seeking), 135–143
addiction stage 4 (lingering vulnerability to relapse), 144–152
aversive effects of high drug doses, 134
biological basis of addiction, 122–123
brain disease theory of SUDs, 123
changes in synaptic microstructure, 156–157
dysfunction of the brain’s “go” and “stop” systems, 123–124
effects on gene expression, 155–156
homeostatic changes to the hedonic set-point, 131–134
how addictive drugs alter brain function, 123–124
long-term memory and risk of relapse, 153–154
neurological basis of positive reinforcement and pleasure, 126–129
neurological substrates of withdrawal syndromes, 130–134
reward circuitry in the brain, 126–129
role of the mesolimbic dopamine system, 126–129
sensitization, 136–139
stages and essential features of addiction, 124–125
vignette (“Sally Quits Using Cocaine … Until She Starts Again”), 121–122
biopsychosocial approach to SUDs, 26–28, 216–218
complex etiology of SUDs, 298–299
nicotine addiction/dependence, 390
relationship to the disease concept of SUDs, 90
risk factors for SUDs, 27–28
bipolar disorder, 259
cocurrence with SUD, 178
genetic factors, 193
prevalence of smoking, 409–410
self-medication with addictive drugs, 262–263
birth defects
contribution of maternal drug use, 20
blood alcohol concentration (BAC)
factors affecting, 311–313
blood-brain barrier, 112–113
potential for development of vaccines against drug effects, 113
Blum, Kenneth, 198, 199
borderline personality disorder, 270, 271–272, 294, 348
co-occurrence with antisocial personality disorder, 274
cocurrence with SUDs, 53, 273–274
Botox, 107
botulism toxin, 107
brain
magnetic resonance imaging (MRI), 23
mesolimbic dopamine system, 97
psychoactive drug interactions with neurotransmitters, 98–99
brain damage
related to alcohol use disorders, 364–370
brain derived neurotrophic factor (BDNF)
effects on neuronal structure, 156–157
brain function and SUDs, 123
addiction stage 1 (reinforcing effects of addictive drugs), 125–129
addiction stage 2 (shift from pleasurable to dysphoric effects), 130–134
addiction stage 3 (compulsive drug-seeking), 135–143
addiction stage 4 (lingering vulnerability to relapse), 144–152
aversive effects of high drug doses, 134
biological basis of addiction, 122–123
brain disease theory of SUDs, 123
brain imaging, 185–190
changes in synaptic microstructure, 156–157
differences as cause or consequence of SUDs, 181
dopamine D2 receptor density, 187–190
dysfunction of the brain’s “go” and “stop” systems, 123–124
EEG abnormalities, 181–182
effects on gene expression, 155–156
genetically determined differences in brain function, 181–190
greater response to psychological stress, 184–185
homeostatic changes to the hedonic set-point, 131–134
how addictive drugs alter brain function, 123–124
impairment of the “stop-system” and “go-system”, 139–143
involvement of prefrontal cortical structures, 140–143
long-term changes in brain function, 153–154
long-term memory and risk of relapse, 153–154
lower response to alcohol, 183–184
magnetic resonance imaging (MRI) studies, 186
neurological basis of positive reinforcement and pleasure, 126–129
neurological substrates of withdrawal syndromes, 130–134
nucleus accumbens, 126–129
positron emission tomography (PET), 186–190
research with family history positive (FHP) subjects, 181
reward circuitry in the brain, 126–129
role of the mesolimbic dopamine system, 126–129
sensitization, 136–139
stages and essential features of addiction, 124–125
ventral tegmental area, 126–129
brain imaging
brain activity related to craving, 243–244
genetic influence on SUDs, 185–190
use in diagnosis of SUDs, 61
brain structure and activity investigations, 22–24
Brevital, 600
brief intervention, 56, 635, 663
Brown, Jackson, 486
Buckley, William F., Jr., 286
buprenorphine, 13, 552, 553, 572, 585
concurrent use with benzodiazepines, 609–610
effect duration, 556
management of opioid addiction, 587
nonmedical use, 568
partial agonist action, 108
bupropion, 430–431, 534
Burger’s disease, 421
Burroughs, William, 545, 558
caffeine, 108, 487
CAGE test, 57
Campral, 100, 244, 375, 635
cancer risk related to smoking, 421
candidate-gene association studies, 198
cannabinol (CBD), 479
cannabinoid receptors, 556
discovery of, 447–448
cannabinoids, 100–101, 129, 447
illicit use of synthetic cannabinoids, 476–477
medical use, 477–480
marijuana, 99
alternative names for, 439
as a “gateway substance”, 468–469
bioavailability of THC, 122–124
effects on brain function, 448–449
endogenous cannabinoid system, 446–449
forms of, 439–440
hashish, 440
high-potency strains, 439–440
identification of THC, 446–447
increased potency over time, 443
pharmacodynamics of THC, 448–449
pharmacokinetics of THC, 445–446
“skunk” cannabis, 439–440
See also tetrahydrocannabinol (THC)
Cannabis sativa varieties, 439
cannabis use
1960s to early twenty-first century, 441–443
acute effects, 449–459
addictive potential, 457, 460–461
adolescents, 466–469
aerosol and vapor delivery systems, 444
alarmist stories and public health concerns, 441
amotivational syndrome, 474–475
analogic effects, 451
Index

798  cannabis use (cont.)

animal studies, 450–451
appetite-increasing effect, 451
behavioral effects, 452–453
biotoxicity, 469–474
challenges for researchers, 449–450
cognitive effects, 452–453
cognitive impairment, 470–474
concurrent with cigarette smoking, 410–411
decriminalisation in some US states, 443
discovery of cannabinoid receptors, 447–448
duration of effects, 445–446
to the United States, 441
legal status, 443
drug effects, 449–450
effects of alcohol consumption, 371
immediate hazardous effects, 457–459
introduction into the United States, 441
legal status, 443
legislation against, 441
lessening of restrictions on, 443
long-term consequences of heavy use, 469–476
medical applications, 451, 477–480
memory and learning impairment, 453
methods of, 444
modes of administration of THC, 445
neurotoxicity, 470–474
physiological effects, 451–452
potential dangers of, 438
prevalence of, 438, 444
prevalence of use and SUDs, 8–9
Reagan administration war on drugs, 442
reasons for, 444
Reefer Madness (film, 1936), 441
reinforcement value, 454–457
risk of fatal overdose, 451–452
risk of psychosis, 475–476
Shafer Commission (1972), 442
subjective effects, 454–457
THC in the brain and body, 445–449
tolerance to the effects of THC, 449
vignette (‘Getting High and Getting Down to Work?’), 438

Cannabis use disorders, 459–466
addiction, 459–460
addictive potential of cannabis, 460–461
addictive use of cannabis, 461–463
DSM-5 criteria, 196
entry into cannabis treatment programs, 460–461
risk factors for cannabis dependence, 465–466
symptoms of cannabis dependence, 461–463
treatment of, 480
withdrawal syndrome, 115, 464–465

Cocaine Anonymous, 645
Cocaine Craving Questionnaire, 147
Cocaine Selective Severity Assessment, 528
cocaine use, 128
acute effects, 496–503
agonist effect on dopamine function, 107
animal self-administration studies, 498–499
behavioral effects, 496–498
bioavailability, 493–494

crack cocaine, 491
development of a vaccine against its effects, 113
differences in individual responses, 501–502
dosage effects, 496
ever twenty-first century, 492–493
effects of injecting or inhaling, 502–503
effects on brain function, 494–496
effects on neurotransmitters, 99, 494–496
euphorigic “rush” followed by aversive dysphoria, 502–503

effect of injecting or inhaling, 502–503

early twenty-first century, 492–493
effects of injecting or inhaling, 502–503
effects on brain function, 494–496
effects on neurotransmitters, 99, 494–496

euphorigic “rush” followed by aversive dysphoria, 502–503

effect of injecting or inhaling, 502–503

popular songs about, 486

prevalence of cigarette smoking, 411

prevalence of use and SUDs, 8–9

prevalence of use and use disorders, 492–493

routes of administration, 493

sensitization to drug effects, 109

stimulant effects, 487

subjective effects, 499–500

twentieth century, 488–492

cocaine use disorders, 503–512

drug development and progression, 508–512

antisocial behavior, 519–520

cocaine use binges, 509–510

cognitive impairment, 520–522

concurrent use of other addictive drugs, 509

consequences of heavy use, 512–527

craving, 529–530

dangers of inhalation and intravenous injection, 510–512

development of tolerance, 509

effects on sexual activity, 513–515

experience of a crack cocaine addict, 511

harm to organ systems and biological function, 524–525

neurotoxicity, 522–524

prenatal exposure to cocaine, 525–527

prevalence of addiction among users, 504–506

psychiatric syndromes related to heavy use, 516–519

risk factors for problematic use, 506–507

routes into addiction, 508–509

stereotyped behavior, 515–516

toxic effects, 522–525

treatment of addiction, 533–535

violence and child abuse associated with, 519–520

withdrawal from heavy use, 527–530

codeine, 100, 551

nonmedical use, 568

cognition and SUD, 232–245

craving, 238–245

expectancy effects in SUD, 235–238

social learning theory, 232

cognitive behavioral theory, 232–233, 245, 261

expectancy effects in SUD, 235–238

explanation of addiction, 217

progression of SUD, 248–251

cognitive behavioral therapy (CBT), 234, 244, 533, 635, 664–665

cognitive control impairment in SUDs, 139–143

cognitive dissonance reduction of, 233–234

cognitive mediation, 233–234

influence of psychoactive drugs, 234–235

Cohen, Sidney, 503

Coleridge, Samuel Taylor, 558

Collaborative Study on the Genetics of Alcoholism (COGA), 25, 49, 197–198, 342

Collins, Michael, 399, 400

common factor model of SUD and psychiatric disorders, 260, 268–269

comorbidity

craving, 135–143

drivers of compulsive behavior, 135–136

impairment of frontal cortical structures, 140–143

involvement of prefrontal cortical structures, 140–143

motivation for drugs, 136–139

sensitization, 136–139

Concerta, 489, 493

conditioned compensatory responses, 230–231

opioid drugs, 566

conditioned oppositional responses to drug-related stimuli, 148–149

Conditioned Place Preference paradigm, 498

conditioned responses to drug-related stimuli, 147–149, 228–229

conditioned responses to subliminal stimuli, 231–232

conditioned tolerance, 116

opioid drugs, 561–562, 566

conditioned withdrawal response, 149, 566–567

conditioning

classical conditioning, 218

instrumental conditioning, 218

operant conditioning, 219

social learning theory, 232

cognitive behavioral theory, 232–233, 245, 261

expectancy effects in SUD, 235–238

explanation of addiction, 217

progression of SUD, 248–251

cognitive behavioral therapy (CBT), 234, 244, 533, 635, 664–665

cognitive control impairment in SUDs, 139–143

cognitive dissonance reduction of, 233–234

cognitive mediation, 233–234

influence of psychoactive drugs, 234–235

Cohen, Sidney, 503

Coleridge, Samuel Taylor, 558

Collaborative Study on the Genetics of Alcoholism (COGA), 25, 49, 197–198, 342

Collins, Michael, 399, 400

common factor model of SUD and psychiatric disorders, 260, 268–269

comorbidity

craving, 135–143

drivers of compulsive behavior, 135–136

impairment of frontal cortical structures, 140–143

involvement of prefrontal cortical structures, 140–143

motivation for drugs, 136–139

sensitization, 136–139

Concerta, 489, 493

conditioned compensatory responses, 230–231

opioid drugs, 566

conditioned oppositional responses to drug-related stimuli, 148–149

Conditioned Place Preference paradigm, 498

conditioned responses to drug-related stimuli, 147–149, 228–229

conditioned responses to subliminal stimuli, 231–232

conditioned tolerance, 116

opioid drugs, 561–562, 566

conditioned withdrawal response, 149, 566–567

conditioning

classical conditioning, 218

instrumental conditioning, 218

operant conditioning, 219
Index

conditioning (cont.)
  respondent conditioning, 218
  role in nicotine addiction/dependence, 389–390
conduct disorder, 182, 200, 201, 272, 294, 296, 371
  risk factor for adolescent drug use, 293
consequences of SUDs, 13–26
  extent of use of psychoactive drugs, 5–6
  public health and safety issues, 13
  vignette (“Losing a Good Team Member”), 4–5
context-dependent tolerance, 230
  correlated liability model, 179
  correlational studies
    limitations of, 179–180
  corticotropin releasing factor (CRF), 134, 151, 152, 156, 184, 317
  cortisol, 150, 151, 184, 185
  counseling, 657–662
  counterculture of the 1960s drug use, 545–546
  couples therapy, 667
  CPY2A6 gene
    implication in smoking behavior, 418–419
  CR OxyContin, 572
  crack cocaine, 491
  craving, 136–139, 187, 238–245
  appetitive craving, 405
  aversive/relief-seeking craving, 405
  brain-imaging investigation, 243–244
  cognitive demands of, 242
  conditioned responses to drug-related stimuli, 230–231
  conditioned responses to subliminal stimuli, 231–232
  conditions that produce, 240–242
  impact on working memory, 242
  management and prevention of, 244
  measurement of, 239
  neurological basis of nicotine craving, 395–397
  neurological correlates, 24
  nicotine, 404–406
  nicotine dependence and, 400–401
  relapse prediction and, 240
  craving, 239
  response to drug-related stimuli, 147
  reward craving, 239
  role in addiction, 239–240
  role of the insula in nicotine craving, 405–406
  stimulant drug withdrawal and, 529–530
  CREB (cAMP response element binding protein), 155–156
  cultural anthropology research, 29
  cultural influences on SUD, 246–248
  acceptance of tobacco use, 384
  availability of addictive drugs, 246
  cultural acceptance of intoxication, 246–247
  definition of culture, 246
  effects of prolonged national stress, 248
  interaction with other SUD risk factors, 247–248
  religious influence, 248
  use and attitudes among subcultures, 246
  Cymbalta, 99
  CYP2A6 enzyme
    metabolism of nicotine in the liver, 395
  Dalmane, 602, 606
  date rape drug (flunitrazepam, Rohypnol), 606–607
  defense mechanisms, 87–88, 233–234
  delay discounting, 221–222
  influence on impulsive choice, 284–285
  delta FosB transcription factor, 156, 157
  delta opioid receptors, 549
  dementia
    alcoholic dementia, 365
    Demerol, 551
    denial, 87–88, 234
    dependence.
"See substance dependence"
  depression, 178–179, 194
  co-occurrence with SUD, 53–54, 264–267
  difficulty of nicotine withdrawal, 404
  prevalence of smoking in people with, 407–409
  self-medication, 264–267
  designer drugs, 477
  developmental disorders
    contribution of maternal drug use, 20
    developmental research, 29
  diacetylmorphine.
"See heroin"
  diagnosis of SUDs
    characteristics of individuals with SUDs, 53–54
    compulsive behavior, 39–41
    consideration of differences in personal circumstances, 54
    co-occurring psychiatric disorders, 53–54
    cultural influences on, 51–52
    diagnostic instruments, 37
    diagnostic interview, 62–64
    difficulty of detecting and diagnosing in women, 54
    distinction between screening and diagnostic testing, 56
    distress or disability, 50
    DSM diagnostic criteria, 9–10
    emotional relationship with the drug, 40–41
    essential features of SUDs, 38–41
    establishing thresholds for identification of psychopathology, 49–50
    facilitating accurate self-reporting of substance use, 64
    false-positive evaluation (overdiagnosis), 52
    formal (professional) diagnosis, 36–37
    gender differences in SUDs, 54
    harmful consequences of drug use, 38–39
    heterogeneity of SUDs, 52–54
high-functioning addicts, 51–52
identifying an individual as an alcoholic or a drug addict, 35
impaired control of behavior, 39–41
impulsive behavior, 40
informal diagnosis, 37–38
language used for, 36
objectivity, 51
physiological withdrawal syndrome, 47–48
routes of entry into diagnosis, 55
screening tests, 37
social influences on, 51–52
stages of the diagnostic process, 55
terminology, 36
Three Cs test, 37–38
use of endophenotypes, 196–197
vignette (“Martin’s Diagnosis”), 33–35

Diagnostic and Statistical Manual of Mental Disorders (DSM), 41–49
3rd edition. See DSM-III
4th edition. See DSM-IV
5th edition. See DSM-5
long-term studies and DSM revisions, 48–49
relationship to the disease theory of SUDs, 49
diagnostic instruments and procedures, 55–64
brain imaging, 61
diagnostic interview, 62–64
facilitating accurate self-reporting of substance use, 64
history of deviant or antisocial behavior, 60
medical examination, 61
personality inventory questionnaires, 60
presence of risk factors for SUDs, 61–62
psychiatric evaluation, 60
routes of entry into diagnosis, 55
screening tests for SUDs, 55–60
stages of the diagnostic process, 55
toxicoanalysis, 61
use of additional information, 60–62
diagnostic interview, 62–64
diagnostic systems, 41
categorical approach, 44
dimensional approach, 44
DSM system of the APA, 41–49
ICD system of the WHO, 49
relationship to the disease theory of SUDs, 49
dialectical behavior therapy (DBT), 666–667
diazepam, 262, 314, 596, 602, 605, 606, 608, 611
protein-binding in the bloodstream, 115
withdrawal syndrome, 114
Dick, Danielle, 191
DiClemente, Carlo, 233
Dilaudid
nonmedical use, 568
disease concept of addiction, 217
disease concept of SUDs acceptance by the medical profession, 75
alternative to immorality or personal weakness explanations, 69
basic tenets, 70–71
behavioral manifestations of a disease, 71–73
brain malfunction and, 123
case for brain disease definition of SUDs, 71–73
comparison with the biopsychosocial approach, 70
consequences of acceptance, 78–79
continuing cultural ambivalence regarding SUDs, 77
disorder of nonbiological factors, 83–84
early twenty-first century, 77–79
essential features of addiction (American Society of Addiction Medicine), 71
formation of NIAAA and NIDA, 76–77
historical perspectives, 73–77
immorality and sin view of drug use, 73–74
in diagnostic systems, 49
influence of Alcoholics Anonymous (AA), 74–75
lessening of shame and guilt, 78–79
limitations to the generality of the basic tenets, 84–90
loss of control concept in SUDs, 88–90
Minnesota Model of SUD treatment, 629
neurological dysfunction and compulsive behavior, 82–83
objections to, 79–84
oversimplification of complex causes of SUDs, 83–84
progression in addiction is not inevitable, 85–87
reactive nature of some SUDs, 84–85
relationship to the biopsychosocial explanation, 90
rise in the number of treatment centers, 75
role of nonbiological risk factors in SUDs, 90
shift toward medicalization of addiction treatment, 78
significance of denial and other defense mechanisms, 87–88
skeptical views on, 77–78
SUDs and addiction as primary disorders, 84–85
SUDs without underlying brain disease, 80–82
versions of disease theory, 70
vignette (“A Good Person with a Bad Disease”), 68–69
dishonesty in addictive lifestyle, 11–13
disulfiram, 201, 375–376, 635
| DNA complexity of behavioral genetics, 191–193 |
| DNA marker microarrays, 203 |
| donepezil, 103 |
| dopamine, 99–100 |
| D2 receptor density and addiction, 133–134 |
| D2 receptor density and SUD risk, 187–190 |
| DRD2 A1 allele association with SUDs, 198–199 |
| DRD2 gene, 206 |
| effects of alcohol, 315 |
| genes associated with SUDs, 198–199 |
| homeostatic changes in the mesolimbic dopamine system, 97 |
| mesolimbic dopamine system and SUDs, 126–129 |
| positive reinforcement of drug effects, 126–129 |
| response to drugs, 24 |
| role in reinforcement, 99 |
| dopamine receptors, 105 |
| dorsolateral prefrontal cortex, 142 |
| dose-effect relationship of high drug doses, 134 |
| dose effects of psychoactive drugs, 108 |
| DRD2 A1 association with SUDs, 198–199 |
| DRD2 gene, 206 |
| Drinking: A Love Story (Knapp), 11 |
| dronabinol, 478 |
| drug alcohol as a, 36 |
| scope of meaning, 36 |
| Drug Abuse Warning Network (DAWN), 329 |
| Drug Effects Questionnaire, 17, 221 |
| Drug Enforcement Administration, 479, 582 |
| drug manufacturing procedures to prevent misuse, 572 |
| drug-related stimuli learned associations, 24 |
| DSM-III, 49 |
| DSM-IV, 10 |
| diagnostic criteria for SUD, 9–10 |
| DSM diagnoses and long-term studies of SUD, 48–49 |
| incidence of nicotine addiction/dependence among smokers, 391 |
| measuring severity of alcohol use disorders, 343–344 |
| nomenclature of SUDs, 41–42 |
| revision of criteria for SUDs, 504 |
| substance abuse diagnosis, 42–43 |
| substance dependence diagnosis, 42–43 |
| terminology for severe SUD, 386 |
| DSM-5, 36, 41, 124 |
| cannabis use disorder, 196 |
| cluster B personality disorders, 271–272 |
| criteria for withdrawal from stimulant drug use, 527 |
| diagnostic criteria for alcohol use disorder, 44–45, 349 |
| diagnostic criteria for substance use disorder, 43–44, 45–47 |
| diagnostic criteria for SUD, 9–10 |
| diagnostic criterion of craving, 238 |
| different combinations of diagnostic criteria for SUD diagnoses, 52–53 |
| DSM diagnoses and long-term studies of SUD, 48–49 |
| incidence of nicotine addiction/dependence among smokers, 390–391 |
| measuring severity of alcohol use disorders, 343–344 |
| nicotine withdrawal symptoms, 399–400 |
| nomenclature of SUDs, 41–42 |
| personality disorders, 270 |
| terminology for severe SUD, 386 |
| variability of alcohol use disorders, 343 |
| duloxetine, 99 |
| dynorphins, 155, 549 |
| Earleywine, Mitch, 441 |
| eating disorders, 11 |
| ecstasy (drug), See MDMA electroencephalography (EEG), 24 |
| abnormal delta and theta oscillations, 182 |
| abnormalities associated with SUDs, 181–182 |
| P300 response, 182 |
| electronic cigarettes, 387, 415, 425–428 |
| cannabis delivery systems, 444 |
| use by adolescents, 415 |
| elimination of drugs from the body, 113–115 |
| emotional distress self-medication model, 261–262 |
| emotional relationship with the drug, 40–41 |
| endogenous cannabinoid receptors, 105 |
| endogenous cannabinoid system, 446–448 |
| endogenous cannabinoids, 99, 448–449 |
| effects of alcohol, 316 |
| endogenous opioid receptors, 105 |
| endogenous opioid system, 549–550, 555–556 |
| endogenous opioids definition, 542 |
| effects of alcohol, 170–176 |
| endophenotypes, 203 |
| association with genotypes, 198 |
| for alcohol use disorders, 196 |
Index

use in SUD diagnosis, 196–197
endorphins, 102, 105, 129, 146–147, 185, 316, 549
enkephalins, 105, 316, 549
environment
influence on drug effects, 116–117
interaction with genetic
influences in SUDs, 194–195, 208–209
epidemiological surveys, 21–22
epigenetics, 195
effects of addictive drugs, 155–156
eszopiclone, 613, 614, 616
See also Z-drugs
ethical issues in SUD research, 18
etiology of SUDs, 298–299
European Network of
Genetic and Genomic
Epidemiology (ENGAGE), 417
executive function, 140
exons, 195
expectation
effects in SUD, 235–238
influence on drug effects, 116–117
extended amygdala, 151
Facebook, 632
Fagerström Test for Nicotine
Dependence (FTDN), 391–393
family-associated risk of SUDs, 170
family therapy, 667–668
fat-sequestered drugs, 115
fentanyl, 551–552
introduction of, 543
fentanyl use
effect duration, 556
escalation from prescribed opioids, 572–573
estimates for the United States, 548
features of illicit use, 574–578
nonmedical use, 547, 568, 569
onset of effects, 556
pain management, 262
prevalence of use and SUDs, 8–9
routes of administration, 556
vignette (“Anticipation”), 541
fetal alcohol spectrum disorder, 372–374
first-pass effect, 114
Fletcher, Rafella, 575
flunitrazepam, 606–607
flurazepam, 602, 606
Focalin, 489
Foundation for a Smokefree
America, 430
Franklin, Benjamin, 307
Freud, Sigmund, 87
functional magnetic resonance
imaging (fMRI) of the brain, 24
GABA, 100
effects of alcohol, 313–315
GABA genes
associations with SUDs, 199–200–201
GABA receptors, 105
GABRA1 gene, 200
GABRA2 gene, 200, 201, 203
gambling disorder, 11
Garland, Judy, 601
“gateway substance”
cannabis as, 468–469
Gautier, Théophile, 455
gender differences in SUDs, 54
gene-environment interaction, 195, 201–202
gene expression
CREB (cAMP response
element binding protein)
transcription factor, 155–156
delta FosB transcription
factor, 156
effects of psychoactive
drugs, 195–196
epigenetic effects of
addictive drugs, 155–156
influence of addictive drugs, 155–156
influence of metabotropic
receptor activation, 155
influences on, 195–196
interaction with behavior, 195–196
production of brain-derived
neurotrophic factor
(BDNF), 156–157
generalized anxiety disorder
smoking and, 408
genes related to SUDs
eycholine genes, 200–201
candidate-gene association
studies, 198
COGA study, 197–198
coupling effect of
stratification, 197
dopamine system and the
DRD2 gene, 198–199
GABA genes, 199–201
genes that control alcohol
metabolism, 201–202
identification of specific
SUD-related genes, 197–204
nicotine dependence genes, 202
potential benefits of
identifying, 197
use disorders with illicit
drugs, 202–203
whole-genome association
tests, 203–204
genetic influence on SUDs, 170
adoption studies, 170–172
alcohol use disorders, 173–174
brain imaging, 185–190
complexity of behavioral
genetics, 191–193
cow-currence of different
SUDs, 175
correlated liability model, 179
differences in brain function, 181–190
differential heritability of
alcohol use disorders, 174
difficulty of identifying
specific genes, 191
EEG abnormalities, 181–182
epidemiological evidence, 170–176
family-associated risk of
SUDs, 170
family patterns of SUD
incidence, 168
genetic differences and
SUDs, 191–208
Index

hypothalamic-pituitary-adrenal (HPA) axis
level of activation in response to stress, 184–185
role in addiction relapse, 151–152

ice (form of methamphetamine), 491–492
identification of SUDs, 9–10
illicit drugs identifying genes related to SUDs, 202–203

Immovane, 613
immune system effects of alcohol use disorders, 370–371
impulsive behavior, 40
impulsivity and SUD, 280–286
aspects of impulsivity, 281–282
behavioral tests of impulse control, 284
delay discounting and impulsive choice, 284–285
impulsive behavior as a choice, 286
measurement of impulsivity, 282
neurological factors and impulse-control deficit, 283
positive aspects of impulsive behavior, 286
self-control in hiding problematic drug use, 286
incentive sensitization, 137–138, 147, 231
incentive value of a stimulus, 137, 149

Infant Development, Environment and Lifestyle study (IDEAL), 526
inhalation route of entry of drugs, 112
initial drug use influence of personality factors, 177–178
influence of psychopathology, 177–178

injection (intravenously) route of entry for drugs, 112
injection (muscle or beneath skin) route of entry for drugs, 112
insomnia benzodiazepine receptor agonists (BZRAs), 612–617
drug treatment since 1900, 596–597
types of sleep-promoting drugs, 595
Z drugs, 612–617
instrumental conditioning, 218
insula role in nicotine craving, 405–406
insular cortex, 243
insulin resistance related to smoking, 422
International Classification of Diseases and Related Health Problems (ICD), 49
nicotine withdrawal symptoms, 401
relationship to the disease theory of SUDs, 49
International HapMap project, 203

Intracerebroventricular injection, 243
Intravenous injection of drugs, 112
intravenous injection of drugs, 112
introns, 195
inverse agonist drug action, 108
ionotropic receptors, 155
Iowa Gambling Task, 284
Iversen, Leslie, 441

Jacobs, Andrew, 513
Jellinek, E.M., 74, 75, 83, 86, 89, 325
gamma-delta classification of alcohol use disorders, 353
Jellinek chart of the course of alcoholism, 350
Joel, Janis, 546
journals that report SUD research, 18

judgment cognitive mediation, 233–234
influence of psychoactive drugs, 234–235
JWH-018 (synthetic cannabinoid), 477
K2 (synthetic cannabinoid), 477
Kalivas, P.W., 124
Kappa endorphin receptors, 104
kappa opioid receptors, 549, 550
Keller, Mark, 83
Keyes, Katherine, 22
kidneys role in drug elimination from the body, 113
Klonopin, 603
Knapp, Caroline, 11, 347, 349
Koob, George, 124, 131–134, 135–136, 139, 220, 230, 396–397
Korsakoff’s syndrome, 364–365, 370
Kreek, Mary Jane, 178
Kristofferson, Kris, 341

Lashley, Karl, 153
Lawford, Christopher, 15
Le Moal, Michel, 124, 131–134, 396–397
learned associations drug-related stimuli, 24
learning expectancy effects in SUD, 235–238
role in behavioral flexibility, 218–219
Lewis, Marc, 82–83
Lexington prison/hospital opioid drug studies, 14–15
Librium, 596, 602, 606
life experience and SUDs interaction with genetic influences, 194–195
LifeRing Secular Recovery, 651
lifestyle addictive lifestyle, 11–13
limbic-system reward circuitry, 556
lipid neurotransmitters, 100–101
liver
disease caused by alcohol, 371
first-pass effect, 114
role in drug elimination from the body, 113–114
role in metabolic tolerance, 113–114
long-term memory
risk of SUD relapse and, 153–154
long-term potentiation, 154
longitudinal studies, 19–20
lorazepam, 603
loss of control concept in SUDs, 88–90
LSD, 104, 545
Ludlow, Fitz Hugh, 455, 457
Luminal, 599
Lunesta, 613
MAC test, 60
Macy, Beth, 587–588
magnetic resonance imaging (MRI)
brain studies, 186
use in diagnosis of SUDs, 61
marijuana. See cannabis
Marinol, 478
Matching Familiar Figures Test, 284
Matrix Model for SUD treatment, 533–534
McCabe, Sean, 569–570
McCrae and Costa five-factor theory of personality, 277
MDMA, 487, 530–533
addiction, 532
addictive potential, 531–532
aversive effects, 532
chemical formula, 530
cognitive deficits associated with, 532–533
development of tolerance, 531–532
eye therapeutic use, 530
effects in the brain, 531
effects of prenatal exposure, 533
effects on neurotransmitters, 99, 531
history of use, 530–531
hyperthermia risk, 532
mechanism of action, 107
memory impairment, 532–533
neurotoxicity, 532
potential for further therapeutic use, 531
prevalence of use, 531
Schedule I classification in the United States, 531
sensitivity of women to, 530
street names for, 530
subjective effects, 530
use at “raves” and as a club drug, 530–531
mechanism of action of drugs, 106–108
medical examination
diagnostic use, 61
medical professionals
drug misuse and addiction, 582–584
medical use
cannabidiol (CBD), 479
cannabis and cannabinoids, 477–480
opioid drugs, 541
use and misuse of prescription opioids, 546
memory
long-term memory effects of SUDs, 153–154
working memory impact of craving, 242
Mendelian inheritance, 193
Mercer, Robert, 612
mesolimbic dopamine system, 97
homeostatic changes to the hedonic set-point, 131–134
role in development of SUDs, 126–129
metabolic tolerance, 110, 113–114
metabotropic receptors
influence on gene expression, 155
methadone, 13, 552, 585
concurrent use with benzodiazepines, 609, 610
effect duration, 556
management of opioid addiction, 586
nonmedical use, 568
methamphetamine use
bioavailability, 493–494
dosage effects, 496
eyear twenty-first century, 492–493
effects of injecting or inhaling, 502–503
effects on brain function, 494–496
effects on neurotransmitters, 494–496
euphoric “rush” followed by aversive dysphoria, 502–503
history of, 487–493
“ice” form of the drug, 491–492
incentives to escalate, 503
pharmacodynamics, 494–496
pharmacokinetics, 493–494
prevalence of use and SUDs, 8–9
prevalence of use and use disorders, 492–493
routes of administration, 493
stimulant effects, 487
subjective effects, 499–500
vignette (“The pharmacist dispenses drugs”), 486
See also MDMA
methamphetamine use disorders, 503–512
addiction development and progression, 508–512
antisocial behavior, 519–520
cognitive impairment, 520–522
concurrent use of other addictive drugs, 509
consequences of heavy use, 512–527
craving, 529–530
dangers of inhalation and intravenous injection, 510–512
development of tolerance, 509
effects on sexual activity, 513–515
harm to organ systems and biological function, 524–525
meth mouth, 524–525
methamphetamine use
binges, 509–510
methamphetamine use in the urban gay community, 513
neurotoxicity, 522–524
prenatal exposure to methamphetamine, 525–527
prevalence of addiction among users, 504–506
psychiatric syndromes related to heavy use, 516–519
risk factors for problematic use, 506–507
routes into addiction, 508–509
stereotyped behavior, 515–516
violence and child abuse associated with, 519–520
withdrawal from heavy use, 527–530

Methamphetamine Withdrawal Questionnaire, 528
Methland (Reding), 516–517, 519–520
methohexital, 600
methylphenidate, 9, 128, 487, 493, 498, 534
nonmedical use, 507–508
treatment for ADHD, 489

Michigan Alcoholism Screening Test (MAST), 57
midazolam, 603
Miller, William, 5
mindfulness training, 666
Minnesota Model of SUD treatment, 629
Minnesota Multiphasic Personality Inventory (MMPI), 60
Minnesota Twin Family Study, 177
modafinil, 487, 489, 534
modeling of behavior, 245–246
Moderation Management, 651, 652
molly (drug). See MDMA
Moments of Clarity (Lawford), 15
Monitoring the Future survey, 21, 287–288, 291, 466
monoamine neurotransmitters, 99–100, 102
monoamine oxidase (MAO) levels in tobacco smokers, 397
monoamine-oxidase inhibitors, 99
Monroe, Marilyn, 601
mood disorders, 178–179
role of serotonin, 99
morphine, 99, 100, 262, 551
action of naloxone on, 553
formulations to prevent misuse, 572
half-life, 556
treatment of drug overdose, 554–555, 557

Naloxone, 552
opioid addiction treatment, 588
use in opioid formulations to prevent misuse, 572
Narcan, 552, 588
narcissistic personality disorder, 270, 271, 274–275
narcopys
amphetamine treatment, 489
narcotic definitions, 542
Narcotics Anonymous (NA), 11, 22, 244, 629, 645
informal diagnosis of SUDs, 37
terminology used by, 36
Narcotics Control Act (1956), 545
National Cancer Institute, 388
National Comorbidity Survey, 22, 262
National Council on Alcoholism, 76
National Health Interview Survey, 403
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 21, 50, 86, 309, 343, 345, 632
broadening scope of, 78
formation of, 76–77
National Institute on Drug Abuse (NIDA), 21, 287, 388, 478, 479, 547, 612
formation of, 76–77
scope of, 78
National Institutes of Health, 76
National Institutes of Mental Health, 76
National Survey on Drug Use and Health (NSDUH), 6, 8–9, 21, 258, 262, 291, 309, 342, 345, 390, 444, 461, 531, 547–548, 626

© in this web service Cambridge University Press
www.cambridge.org
Index

Nauta, Walle, 140
negative emotionality and SUD, 280–281
negative reinforcement, 125, 225–226
effects of opioid drugs, 558
Nembutal, 599
NEO Personality Inventory (NEO-PI), 277, 279
neonatal abstinence syndrome, 584–585
neuroadaptation
development of drug tolerance, 109–110
neurobehavior disinhibition
adolescent drug use risk factor, 293–294
neuroimaging, 22–24
use in diagnosis of SUDs, 61
neurological substrates of acute and protracted withdrawal syndromes, 130–134
neurons
functions of, 97
neurotransmitter binding with postsynaptic receptors, 101
neurotransmitter inactivation, 101–102
neurotransmitter release into the synapse, 101
neurotransmitter removal from the synapse, 102
neurotransmitter reuptake at the synapse, 102
neurotransmitter synthesis, 101
receptor binding of neurotransmitters, 103
structural effects of BDNF, 156–157
synaptic plasticity, 157
synaptic structural changes caused by addictive drugs, 156–157
synaptic transmission, 101–103
neuropeptide Y (NP Y), 317
neurotoxicity
effects of stimulant drugs, 522–524
neurotransmitters
acetylcholine, 100
amino acid neurotransmitters, 100
binding to receptors, 103
binding with postsynaptic receptors, 101
cannabinoids, 100–101
diversity of neurotransmitter functions, 103
dopamine, 99–100
drug influence on availability in the synapse, 107
effects of connecting with receptors, 97
effects of MDMA, 531
effects of nicotine, 395–397
effects of stimulant drugs, 494–496
functions in behavior and cognition, 103
GABA, 100
glutamate, 100
identification of, 98–99
inactivation, 101–102
interactions with psychoactive drugs, 98–99
lipid neurotransmitters, 100–101
mechanisms of drug action, 106–108
monoamine class, 99–100
noradrenaline, 99–100
opioid neuropeptide neurotransmitters, 100
psychoactive hormones, 100
receptor types and subtypes, 105
release into the synapse, 101
removal from the synapse, 102
reuptake at the synapse, 102
serotonin, 99–100
synaptic transmission, 101–103
synthesis in neurons, 101
Newlove, Donald, 352
nicotine, 100
addictive potential, 422–425
bioavailability, 394–395
cognitive effects, 398–399
content of cigarettes, 394–395
CYP2A6 enzyme metabolism in the liver, 395
effects on brain function, 395–397
effects on neurotransmitters, 395–397
effects on nonsmokers, 398
effects on smokers and nonsmokers, 394
electronic delivery systems, 425–428
half-life in the body, 395
inhaled and nasal spray, 431
insecticidal property, 394
modes of access into the body, 394
neurological basis of craving, 395–397
pharmacodynamics, 395–397
pharmacokinetics, 394–395
physiological effects, 398
recognition of its addictive potential, 51
role of acetylcholine receptors in development of tolerance, 395–396
stimulant effect, 487
toxic effects of low doses, 394
toxicity of, 394
transdermal patches, 398
See also tobacco use nicotine addiction/dependence
appetitive craving, 405
approaches to treating, 428–430
aversive/relief-seeking craving, 405
biopsychosocial view, 390
cancer risks, 421
comparison with alcohol use disorders, 384–385
concurrent use of other addictive drugs, 410–411
consequences of adolescent smoking, 415–416
co-occurrence with psychiatric disorders, 263–264
definitions of addiction and dependence, 386
determining the incidence among smokers, 390–394
difficulty of stopping smoking, 403
difficulty of stopping smoking with co-occurring psychiatric disorders, 406–407
© in this web service Cambridge University Press
www.cambridge.org
DSM assessment of incidence among smokers, 390–391
electronic cigarettes, 425–428
Fagerström Test for Nicotine Dependence (FTDN), 391–393
genes related to, 202
Heaviness of Smoking Index (HIS), 392
hormonal factors in women, 413
lifestyle effects, 12
light smokers (“chippers”), 390
mechanisms of toxicity, 421
medications to help smoking cessation, 430–431
Nicotine Dependence Syndrome Scale (NDSS), 393
nicotine metabolism and CPY2A6 gene alleles, 418–419
nicotine substitution therapy, 392
NSDUH 2017 survey, 390
personality traits and, 411–412
premature deaths caused by, 420
promotion by reinforcement, 388–389
reward value of nicotine, 423–424
risk factors for, 383
role of CHRNA5 gene alleles, 419
role of conditioning, 389–390
role of orexin, 406
stopping smoking, 428–431
synergistic toxic risk, 422
twelve-step programs and, 428–430
two studies on use and dependence, 174
vignette (“Thinking about Stopping Smoking”), 382–383
weight gain on stopping smoking, 413
Wisconsin Inventory of Smoking Dependence Motives, 393–394
withdrawal relief and, 401–404
women’s lower success in stopping smoking, 412–413
See also tobacco use
Nicotine Anonymous, 383, 429–430
Nicotine Dependence Syndrome Scale (NDSS), 393
nicotine replacement therapy (NRT), 413, 421, 431
nicotine withdrawal syndrome, 174, 399–406
animal models, 401
Cigarette Withdrawal Scale, 402–403
craving, 400–401, 404–406
effects of anxiety or depressive disorders, 404
intensity in individuals with psychiatric disorders, 406–407
irritability and anxiety symptoms, 399–400
motivation for continued abstinence, 401–404
neurological basis, 395–397
particular effects in women, 412–413
time course of symptoms, 399–400
tolerance for distress, 404
withdrawal relief and dependence, 401–404
nicotinic acetylcholine receptors, 395–396
Niebuhr, Reinhold, 646
Night of the Gun (Carr), 11
Nixon, Richard, 442
nomenclature of SUDs
DSM system, 41–42
nondisabled remission and recovery, 669–672
nonbiological factors
influence on addictive behavior, 216
nongenetic factors
influence on SUD risk, 194–195
noradrenaline, 99–100, 129, 151
role in relapse to drug use, 99
noradrenaline receptors, 105
nucleus accumbens, 151, 156, 195, 555
role in SUDs, 126–129
obesity
use of amphetamine for weight loss, 489
odds ratios for risk factors, 193
Office on Smoking and Health, 388
ondansetron, 356
operant conditioning, 219
opiate
definition, 542
opioid
definition, 542
opioid addiction
buprenorphine (partial agonist) treatment, 587
management via drug treatment, 585–588
medical management of, 13
methadone maintenance, 586
resistance to provision of medication-assisted treatment (MAT), 587–588
treatment with opioid antagonists, 588
opioid analgesic drugs, 48
prevalence of use and SUDs, 8–9
opioid drugs
agonists, 550
analgesia, 100, 554–555, 557–558
antagonists, 550
aversive side effects, 560
behavioral effects, 557–560
bioavailability, 556
conditioned compensatory response, 566
conditioned tolerance, 561–562, 566
Index

opioid drugs (cont.)
conditioned withdrawal response, 566–567
consequence of long-term use, 560–564
development of tolerance, 561–562
effects on brain function, 553–556
endogenous opioid system, 549–550
euphoria caused by, 558–560
hyperalgesia induced by, 563
interaction with the endogenous opioid system, 555–556
manufacturing procedures to prevent misuse, 572
medical use, 541
mixed agonist-antagonist agents, 550
negative reinforcement effects, 558
opioid receptors, 549
partial agonists, 550
pharmacodynamics, 553–556
pharmacokinetics, 556
physiological effects, 557–560
positive reinforcement, 558–560
positive reinforcement mechanisms, 555–556
protracted withdrawal syndrome, 563–564
receptors activated by, 104
risks related to the addictive lifestyle, 563
routes of administration, 556
subjective effects, 557–560
terminology, 542
variation in effect duration, 556
withdrawal syndrome, 562–563
opioid misuse and use disorders, 564–585
behaviors suggestive of addiction, 579–580
dependency and addiction in chronic-pain patients, 578–582
dependence in the absence of a use disorder, 565
distinguishing between dependence and addiction, 578–579
drug manufacturing procedures to prevent misuse, 572
fentanyl use, 574–578
four types of, 567–584
general features of, 564–567
heroin use, 573–578
increasing rates of, 541–542
misuse and addiction by medical professionals, 582–584
misuse of pharmaceutical opioids, 567–573
neonatal abstinence syndrome, 584–585
pseudoaddiction, 578, 579–580
vignette (Anticipation), 541
withdrawal syndrome in addicts, 565–567
opioid neuropeptide neurotransmitters, 100
opioid peptide neurotransmitters, 99, 549
opioid receptors, 549
delta opioid receptors, 549
kappa opioid receptors, 549, 550
mu opioid receptors, 549, 550, 553–554, 555–556
Opioid Risk Tool, 581
opioid use and misuse
AIDS and intravenous drug use, 546
CDC guidelines for opioid prescription, 548
history of, 542–548
opioid misuse “epidemic” in the United States, 546–548
prescription opioids, 546
twentieth century, 543–546
twenty-first century, 546–548
Vietnam conflict, 545
opioid, 542–543
opium poppy (Papaver somniferum), 542
oppositional defiant disorder, 296
orbitofrontal cortex, 142
orexin
role in nicotine dependence, 406
oxazepam, 603
Oxford-GlaxoSmithKline (Ox-GSK) consortia, 417
oxidative stress related to smoking, 421, 422
oxycodone, 9, 551, 568
formulations, 556
formulations to prevent misuse, 572
nonmedical use, 568, 569
OxyContin, 9, 509, 541, 551, 568
nonmedical use, 568
pain management
analogic effects of opioid drugs, 554–555, 557–558
distinguishing between opioid dependence and addiction, 578–579
hyperalgesia induced by opioid drugs, 563
opioid dependence and addiction in chronic-pain patients, 578–582
opioid withdrawal syndrome in chronic-pain patients, 578
use and misuse of prescription opioids, 546
panic-spectrum disorder
smoking and, 408
paranoid personality disorder, 275
paranoid psychosis
stimulant drug-induced, 516–519
parenting practices
adolescent drug use and, 295–296
Pavlov, Ivan, 153, 218
Pavlovian conditioning, 147
peer pressure, 224, 246
pentobarbital, 598, 599
Percoct, 568
Percodan, 551, 568
personal accounts of drug addiction, 14–16
personality disorders
co-occurrence with SUDs, 53–54
personality factors, 276
genetic predisposition for SUDs, 177–180
influence on initial drug use, 177–178
influence on transition to SUDs, 178–179
limitations of correlational studies, 179–180
personality inventory questionnaires, 60
personality research, 29, 276–277
personality theory, 275–281
Cloninger’s tridimensional theory, 277–278
drug-specific personality factors, 279–280
impulsivity and SUD, 280–281
McCrae and Costa five-factor theory, 277
multiple-drug-use personality factors, 279–280
negative emotionality and SUD, 280–281
personality factors, 276
personality traits, 275–276
Tellegen’s three-factor theory, 278–279
personality traits, 275–276
association with nicotine dependence, 411–412
personality types and disorders addictive personality concept, 270–271
antisocial personality disorder, 271–273
avoidant personality disorder, 275
borderline personality disorder, 271–272, 273–274
categorical models, 271
dimensional models, 271
disorders associated with SUD, 271–275
DSM-5 cluster B personality disorders, 271–272
DSM-5 personality disorders, 270
histrionic personality disorder, 274
narcissistic personality disorder, 274–275
paranoid personality disorder, 275
personality concept, 148–149
pharmaceutical drugs misuse of opioid drugs, 567–573
nonmedical use of stimulants, 507–508
opioid misuse “epidemic” in the United States, 546–548
prevalence of stimulant use and use disorders, 492–493
pharmacodynamic tolerance, 109–110, 130, 230
pharmacodynamics, 106–110
agonist drug action, 106–108
alcohol, 313–317
antagonist drug action, 106–108
definition, 106
definition of tolerance, 109
direct drug interaction with receptors, 107–108
dose effects of psychoactive drugs, 108
drug binding with receptors, 107–108
drug influence on neurotransmitter availability in the synapse, 107
homeostatic processes in the CNS, 109
inverse agonist drug action, 108
mechanism of action of drugs, 106–108
neuroadaptation and drug tolerance, 109–110
partial agonist drug action, 108
receptor density up- or down-regulation, 109–110
role of autoreceptors, 109
sensitization to drug effects, 109
withdrawal syndrome, 110
pharmacokinetics, 111–115
alcohol, 311–313
blood-brain barrier, 112–113
definition, 106
elimination of drugs from the body, 113–115
factors affecting bioavailability of a drug, 111
first-pass effect, 114
influence of strength and duration of drug effects, 114
mechanism of the “euphoric rush”, 113
metabolic tolerance, 113–114
potential development of vaccines against drug effects, 113
protein-binding of drugs in the bloodstream, 114–115
routes of drug administration, 112
withdrawal syndrome, 114
phenecyclidine, 107
receptor binding, 108
phenmetrazine, 487
phenobarbital, 596, 599
phenotypes, 192
Phoenix, River, 576
physician health program (PHP), 583–584
physiological dependence
DSM-5 meaning, 42
physiological view of addiction, 10–11
physiological withdrawal syndrome, 47–48
pipe smoking, 420
pleasurable effects of drugs
neurological basis, 126–129
subjective pleasure and positive reinforcement, 222–223
polymorphisms, 192
positive reinforcement, 219–225
delay discounting, 222
delay time and reinforcement strength, 221–222
detetection and measurement, 220–221
direct and indirect sources of, 223–224
intermittent reinforcement, 224–225
neurological basis, 126–129
Index

positive reinforcement (cont.)
neurological basis of positive reinforcement and pleasure, 126–129
opioid drug use, 555–556, 558–560
power of alternative reinforcements, 224
role in development of addiction, 125
subjective pleasure and, 222–223
value of immediate rewards, 221–222
positron emission tomography (PET), 186–190
imaging of the brain, 24
use in diagnosis of SUDs, 61
posttraumatic stress disorder (PTSD), 531
co-occurrence with SUD, 267–268
in children, 296
self-medication, 267–268
smoking and, 408
prefrontal cortex, 126, 127
structures involved in compulsive drug-seeking, 140–143
pregnancy
effects of fetal exposure to nicotine, 421
effects of prenatal exposure to cocaine, 525–527
effects of prenatal exposure to MDMA, 533
effects of prenatal exposure to methamphetamine, 525–527
opioid drug use and neonatal abstinence syndrome, 584–585
risks of smoking during, 422
prenatal exposure to drugs.
See pregnancy
prescription opioids
opioid misuse “epidemic” in the United States, 546–548
use and misuse of, 546, 567–573
prison
Lexington prison/hospital
opioid drug studies, 14–15
process addictions, 10–11
Profile of Mood States (POMS), 17, 128, 147, 221, 454, 528
progesterone
influence on stimulant drug effects, 501
progression in addiction, 85–87, 248–251
protein binding of drugs in the bloodstream, 114–115
Provigil, 489, 534
Pryor, Richard, 503
pseudoaddiction
behaviors suggestive of, 579–580
opioid pain treatments and, 578
psychiatric disorders and SUD, 269
common factor model, 260, 268–269
cocurrence, 53–54
effects of smoking on psychiatric drug metabolism, 410–412
geneic predisposition to both disorders, 268–269
incidence of co-occurrence, 257–258
intensity of nicotine withdrawal symptoms, 406–407
models of interaction between, 258–269
odds ratios for co-occurrence, 259
prevalence of smoking tobacco, 406–410
secondary psychopathology model, 260–261
secondary SUD model, 260, 261–268
self-medication model, 260, 261–268
vignette (“Preparing for the Job Interview”), 257
psychiatric evaluation, 60
psychiatric syndromes related to heavy stimulant drug use, 516–519
psychotropic drug use
breadth and complexity of, 5–6
for consciousness-altering effects, 6–7
for pleasurable effects, 6–7
hazards of, 7–8
incentives for, 6–7
medical reasons for, 6–7
public health and safety issues, 5–6
utilitarian reasons for, 6–7
variety of pathways into addiction, 217
psychoactive drugs
interactions with brain and body functions, 106
interactions with neurotransmitters, 98–99
psychoanalysis, 628
psychoanalytic theory, 87, 88
psychological stress
geneically determined response, 184–185
level of HPA axis activation, 184–185
psychological view of addiction, 10–11
psychopathology
geneic predisposition for SUDs, 177–180
influence on initial drug use, 177–178
influence on transition to SUDs, 178–179
limitations of correlational studies, 179–180
psychopathology research, 29
psychopharmacology
behavioral tolerance, 115–116
nonpharmacological influences on drug effects, 116–117
pharmacodynamics, 106–110
pharmacokinetics, 111–115
research on pharmacological treatment of addiction, 117
set and setting influences on drug effects, 116–117
vignette (“I Want a New Drug”), 96–97
psychosis
risk related to cannabis use, 475–476
psychotherapy, 657–662
public health and safety issues
approach of the ICD system of the WHO, 49
stimulant drug use, 519–520
**Index**

- **Index 813**
- **punding, 515–516**
- **Purple Haze (synthetic cannabinoid), 477**
- **quantitative trait loci (QTLs) studies with inbred mice, 205–206**
- **R.J. Reynolds Tobacco Company, 386**
- **Raistrick, Duncan, 364**
- **Rapid Alcohol Problems Screen (RAP5), 57–58**
- **rating scales, 17**
- **Rational Recovery, 651**
- **rationalization defense mechanism, 87, 88, 234**
- **Reagan, Nancy**
  - **Just Say No campaign, 442**
- **Reagan administration war on drugs, 442**
- **receptors**
  - **autoceptors, 105**
  - **binding of neurotransmitters, 103**
  - **cannabinoid receptors, 447–448, 556**
  - **delta opioid receptors, 549**
  - **density regulation in response to drugs, 109–110**
  - **dopamine D2 receptor density and addiction, 133–134**
  - **dopamine D2 receptor density and SUD risk, 187–190**
  - **dopamine D4 receptors, 199**
  - **drug binding with, 107–108**
  - **excitatory effects, 104**
  - **fast-acting receptors, 104**
  - **GABA receptors, 200**
  - **inhibitory effects, 104**
  - **interactions with abused or addicting drugs, 104**
  - **ionotropic actions, 104**
  - **ionotropic receptors, 155**
  - **kappa endorphin receptors, 104**
  - **kappa opioid receptors, 549, 550**
  - **metabotropic actions, 104**
  - **metabotropic receptor activation and gene expression, 155**
  - **mu endorphin receptors, 104**
- **mu opioid receptors, 549, 550, 553–554, 555**
- **neurotransmitter binding with postsynaptic receptors, 101**
- **nicotinic acetylcholine receptors, 395–396**
- **opioid receptors, 549**
- **role in drug tolerance development, 105**
- **serotonin 5HT2 receptors, 104**
- **slower-acting receptors, 104**
- **types and subtypes, 105**
- **recovery definition, 635**
- **nonabstinent recovery, 669–672**
- **Reding, Nick, 516–517, 519–520**
- **Reed, Lou, 610**
- **Reefer Madness (film, 1936), 441**
- **reinforcement intermittent reinforcement, 224–225**
- **power of alternative reinforcements, 224**
- **promotion of nicotine addiction/dependence, 388–389**
- **reinforcing effects of addictive drugs, 125–129**
- **role in addictive behavior, 219**
- **role of dopamine, 99**
- **See also negative reinforcement; positive reinforcement reinstatement (RI) model in animals, 152**
- **relapse abstinence violation effect, 668–669**
- **compensatory conditioning to drug-related stimuli, 148–149**
- **conditioned oppositional responses to drug-related stimuli, 148–149**
- **conditioned responses to drug-related stimuli, 147–149**
- **conditioned withdrawal response, 149**
- **definition, 668**
- **HALT (hunger, anger, loneliness, fatigue [tired]) risk factors, 149–150**
- **lingering vulnerability to, 144–152**
- **prevention, 668–669**
- **recurrence of drug-seeking in experimental animals, 145–146**
- **reinstatement (RI) model in animals, 145–146–147, 152**
- **risk factors for, 144–152**
- **risk of exposure to drug-related stimuli, 147–149**
- **risk related to long-term memory effects, 153–154**
- **risk with reexposure to the addictive drug, 146–147**
- **role of noradrenaline, 99**
- **role of the HPA axis, 151–152**
- **stress risk factor, 149–152**
- **use of craving to predict, 240**
- **religiosity expectations about effects of alcohol, 238**
- **influence on addictive drug use, 248**
- **spirituality of Alcoholics Anonymous, 645–647**
- **remission definition, 635**
- **factors promoting untreated remission, 643–644**
- **nonabstinent remission, 669–672**
- **untreated remission of SUD, 640–644**
- **Remoxy, 572**
- **Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 326**
- **research specialized research areas related to SUDs, 28–29**
- **research methods, 14–26**
- **anecdotal accounts of drug addiction, 14–16**
- **animal models of addiction, 25–26**
Index

brain structure and activity investigations, 22–24
controlled experiments, 16–18
electroencephalography (EEG), 24
epidemiological surveys, 21–22
ethical issues, 18
fMRI of the brain, 24
identifying the contribution of various risk factors, 20
investigations of genetic vulnerability to SUDs, 25
journals which report SUD research, 18
Lexington prison/hospital opioid drug studies, 14–15
limitations of direct observation, 14–16
longitudinal studies, 19–20
magnetic resonance imaging (MRI) of the brain, 23
multivariate statistical analysis, 20, 22
neuroimaging, 22–24
personal accounts of drug addiction, 14–16
PET imaging of the brain, 24
quasi-experimental studies, 18–19
rating scales, 17
standardized instruments, 17
systematic studies of addicted individuals, 18–19
residential treatment programs, 654–655
respondent conditioning, 218
Ritalin, 9, 128, 487, 489, 493, 498, 534
nonmedical use, 507–508
Robinson, T.E., 220
Rolynplo, 606–607
Rolling Stones, 596
routes of drug administration, 112
Rush, Benjamin, 74, 75
schizophrenia co-occurrence with SUD, 178
genetic factors, 193
schizophrenia patients effects of smoking on antipsychotic medication metabolism, 410–412
prevalence of smoking, 409–410
self-medication with addictive drugs, 262–263
Schrieck, Ilse, 17
Schuckit, Marc, 183–184, 227–228
scopolamine, 103
screening tests for SUDs, 37, 55–60
accuracy of self-report tests, 59–60
definition of screening, 56
distinction from diagnostic testing, 56
populations appropriate for screening, 56–57
risk of false-positive and false-negative errors, 58–60
sensitization, 154
behavioral sensitization, 136–137
compulsive drug-seeking and, 136–139
incentive sensitization, 137–138, 147
to drug effects, 109
Secobarbital, 599
Secominal, 600
secondary psychopathology model, 260–261
secondary SUD model, 260, 261–268
anxiety disorder, 264–267
bipolar disorder, 262–263
depression, 264–267
emotional distress self-medication, 261–262
nicotine dependence and psychiatric disorders, 263–264
posttraumatic stress disorder (PTSD), 267–268
schizophrenia, 262–263
secrecy in addictive lifestyle, 11–13
secular mutual assistance groups, 650–652
Secular Organization for Sobriety (SOS), 651
sedative-hypnotic drugs barbiturates, 598–601
benzodiazepine receptor agonists (BZRAs), 596–597
misuse of, 597–598
types of anti-insomnia drugs, 595
sedatives prevalence of use and SUDs, 8–9
treatment of sedative use disorders, 617
selective attention, 233
self-awareness, 245
self-efficacy, 233, 244
self-medication explanation of SUDs, 179
for nondrug problems, 180
posttraumatic stress disorder (PTSD), 267–268
self-medication model, 260, 261–268
anxiety disorder, 264–267
bipolar disorder, 262–263
depression, 264–267
emotional distress, 261–262
nicotine dependence and psychiatric disorders, 263–264
schizophrenia patients, 262–263
sensitization, 154
behavioral sensitization, 136–137
compulsive drug-seeking and, 136–139
incentive sensitization, 137–138, 147
to drug effects, 109
Serax, 603

risk factors for SUDs, 27–28, 251
reward delay discounting, 221–222
reward circuitry in the brain, 126–129
reward deficiency hypothesis, 134
reward deficiency syndrome, 188
reward deficiency theory, 199, 221
reward value cannabis, 454–457
nicotine, 423–424
stimulant drugs, 498–499
rimonabant, 316, 449, 454, 464
emotional distress self-medication, 261–262
nicotine dependence and psychiatric disorders, 263–264
posttraumatic stress disorder (PTSD), 267–268
schizophrenia, 262–263
secrecy in addictive lifestyle, 11–13
secular mutual assistance groups, 650–652
Secular Organization for Sobriety (SOS), 651
sedative-hypnotic drugs barbiturates, 598–601
benzodiazepine receptor agonists (BZRAs), 596–597
misuse of, 597–598
types of anti-insomnia drugs, 595
sedatives prevalence of use and SUDs, 8–9
treatment of sedative use disorders, 617
selective attention, 233
self-awareness, 245
self-efficacy, 233, 244
self-medication explanation of SUDs, 179
for nondrug problems, 180
posttraumatic stress disorder (PTSD), 267–268
self-medication model, 260, 261–268
anxiety disorder, 264–267
bipolar disorder, 262–263
depression, 264–267
emotional distress, 261–262
nicotine dependence and psychiatric disorders, 263–264
schizophrenia patients, 262–263
sensitization, 154
behavioral sensitization, 136–137
compulsive drug-seeking and, 136–139
incentive sensitization, 137–138, 147
to drug effects, 109
Serax, 603
serotonin, 99–100, 103, 129
effects of alcohol, 315
role in mood disorders, 99
serotonin receptors, 105
set and setting influences on drug effects, 116–117
set-point.
See hedonic set-point
sexual activity
aphrodisiac effect of stimulant drugs, 507
effects of alcohol, 321–322
effects of stimulant drugs, 513–515
sexual assault
drug facilitated, 606–607
Sheff, Nic, 11
Shiffman, Saul, 668
Siegel, Shepard, 230
Sildenafil, Robert, 645
Silverstein, Shel, 463
Simon, Paul, 456
Sims, Zoot, 545
single-nucleotide polymorphisms (SNPs), 197, 203
Skinner, B.F., 218
Skinner box, 219
Slovak, Hillel, 576
SMART Recovery, 632, 645, 651
smoking.
See nicotine addiction/dependence; tobacco use
snuff, 385, 420
social anxiety disorder, 275, 408
social cognition research, 29
social influences on SUD, 245–246
modeling of behavior, 245–246
social learning theory, 232
social media
information on SUDs and treatment, 632–633
Society for Neuroscience, 25
socioeconomic status
adolescent drug use and, 296
Sonata, 515
sports
use of performance-enhancing stimulant drugs, 497
SSRI drugs, 596
side effects, 601
Stahl, Stephen, 140
stereotyped behavior
caus ed by heavy use of stimulant drugs, 515–516
stimulant drug use
acute effects, 496–503
animal self-administration studies, 498–499
behavioral effects, 496–498
bioavailability, 493–494
differences in individual responses, 501–502
dosage effects, 496
ey early twenty-first century, 492–493
effects of injecting or inhaling, 502–503
effects on brain function, 494–496
effects on neurotransmitters, 494–496
 euphoric “rush” followed by aversive dysphoria, 502–503
history of, 487–493
hormonal influences on effects, 501
incentive to escalate, 503
influence of stress on effects, 502
medical uses, 489
performance-enhancing effects, 496–497
pharmacodynamics, 494–496
pharmacokinetics, 493–494
physiological effects, 496–498
prevalence of use and SUDs, 8–9
reasons for using, 487
reward value of stimulant drugs, 498–499
routes of administration, 493
subjective effects, 499–500
twentieth century, 488–492
types of stimulant drugs, 487
vignette (“The Pharmacist Dispenses Drugs”), 486
stimulant use disorders, 503–512
addiction development and progression, 508–512
antisocial behavior, 519–520
cognitive behavioral therapy (CBT), 533
cognitive impairment, 520–522
concurrent use of other addictive drugs, 509
consequences of heavy use, 512–527
craving, 529–530
dangers of inhalation and intravenous injection, 510–512
development of tolerance, 509
drug-induced paranoid psychosis, 516–519
effects of prenatal exposure to stimulant drugs, 525–527
effects on sexual activity, 513–515
harm to organ systems and biological function, 524–525
Matrix Model approach to treatment, 533–534
neurotoxicity, 522–524
nonmedical use of pharmaceutical stimulants, 507–508
prevalence of addiction among users, 504–506
psychiatric syndromes, 516–519
public health and safety issues, 519–520
risk factors for problematic use, 506–507
routes into addiction, 508–509
stereotyped behavior, 515–516
stimulant use binges, 509–510
toxic effects of stimulants, 522–525
treatment of addiction, 533–535
violence and child abuse associated with, 519–520
withdrawal from heavy use, 527–530
stimulus control of SUD, 228–232
conditioned compensatory responses, 230–231
conditioned responses to drug-related stimuli, 228–229
conditioned responses to subliminal stimuli, 231–232
context-dependent tolerance, 230
craving, 230–231
stimulus-elicited responses, 147–149
Stop Signal Task, 284
stratification
confounding effect in gene studies, 197
stress
childhood stress and adolescent drug use, 295–296
genetically determined response to psychological stress, 184–185
hormonal responses to, 151
influence on effects of stimulant drugs, 502
level of HPA axis activation, 184–185
prolonged national stress and SUD rates, 248
risk factor for relapse, 149–152
role in vulnerability to addiction, 149
stress responses to withdrawal influence in shifting the hedonic set-point, 134
Stroop test, 284
Structured Clinical Interview for DSM (SCID), 62
Study of Addiction: Genetics and Environment (SAGE), 204
Sublimaze, 551–552
nonmedical use, 568
Suboxone, 552, 572, 587
substance abuse
DSM-IV definition, 10, 42
DSM-IV diagnostic criteria, 42–43
meaning of the term, 36
Substance Abuse and Mental Health Services Administration (SAMHSA), 21
Substance Abuse Subtle Screening Inventory (SASSI), 60
substance dependence
DSM-IV definition, 10, 42
DSM-IV diagnostic criteria, 42–43
substance use disorders (SUDs) addictive lifestyle, 11–13
biopsychosocial explanation, 26–28
definition of substance use disorder, 8
diagnosis, 9–10
DSM diagnostic criteria, 9–10
DSM-5 designations, 42
essential features of, 38–41
heterogeneity of, 52–54
identification, 9–10
identifying causes and consequences, 13–26
physiological and psychological views, 10–11
prevalence of, 8–9
research methods, 14–26
significance of a withdrawal syndrome, 10–11
use of the term substance use disorder, 36
Subutex, 552, 585, 587
suicidal thinking
nicotine addiction and, 409
suicide
risk related to alcohol use, 327–328
Susann, Jacqueline, 601
synaptic microstructure
changes causes by addictive drugs, 156–157
synaptic plasticity, 157
synaptic transmission, 101–103
development of tolerance, 103
drug influence on neurotransmitter availability, 107
neurotransmitter binding with postsynaptic receptors, 101
neurotransmitter inactivation, 101–102
neurotransmitter release into the synapse, 101
neurotransmitter removal from the synapse, 102
neurotransmitter re-uptake, 102
neurotransmitter synthesis, 101
receptor binding of neurotransmitters, 103
regulatory processes, 103
synthetic cannabinoids illicit use of, 476–477
Synthetic Drug Abuse Prevention Act (2012), 477
Szalavitz, Maia, 500, 649–650
T-ACE test, 57
Tellegen’s three-factor theory of personality, 278–279
tetrahydrocannabinol (THC), 99, 101, 316
content in cannabis, 439–440
fat-sequestration, 115
See also cannabis.
thiamine
deficiency in alcohol use disorders, 369–374
thorazine, 108
Thorndike, Edward, 218
Three Cs test (compulsion, control, consequences) for SUDs, 37–38, 390–391
thresholds for identification of psychopathology, 49–50
Tiffany, Stephen, 240
Tobacco and Genetics Consortium (TAG), 417
tobacco use
behavior of addictive tobacco use, 388–390
biopsychosocial view, 390
cancer risks, 421
carcinogenic effects, 421
cardiovascular disease associated with, 421–422
changing attitudes over time, 51, 247–248
comparison with alcohol use disorders, 384–385
concurrent use of other addictive drugs, 410–411
consequences for adolescents, 415–416
COPD associated with, 422
cultural acceptance of, 384
difficulty of stopping smoking, 403
diseases caused by or related to, 421–422
effects of passive exposure to tobacco smoke, 420–421
effects on metabolism of antipsychotic medications, 410–412
factors in maintaining abstinence, 401–404
genetics of smoking and nicotine dependence, 417–419
half-life of nicotine in the body, 395
health risks of smoking in women, 385
legality of, 384
mechanisms of toxicity, 421
medications to help smoking cessation, 430–431
mortality associated with, 383
nicotine content of cigarettes, 394–395
passive exposure to smoke ("second-hand smoke"), 385
premature deaths caused by, 420
prevalence in bipolar disorder, 409–410
prevalence in different age groups, 383–384
prevalence in people with anxiety disorders, 407–409
prevalence in people with depression, 407–409
prevalence in people with psychiatric disorders, 406–410
prevalence in schizophrenia patients, 409–410
prevalence of different types of, 383–384
prevalence of use and SUDs, 8–9
promotion by conditioning, 389–390
promotion by reinforcement, 388–389
risk in women who take oral contraceptives, 422
risks during pregnancy, 422
smoking in adolescents, 414–417
smoking in women, 412–413
social acceptability, 384
stopping smoking, 428–431
synergistic toxic risk, 422
tar in tobacco and tobacco smoke, 394
toxic compounds in tobacco and tobacco smoke, 394
toxic consequences, 386–387
toxicity of nicotine, 394
vignette ("Thinking about Stopping Smoking"), 382–383
weight gain on stopping smoking, 400
See also nicotine; nicotine addiction/dependence tobacco use in the United States
chewing tobacco, 385
cigarette smoking, 385–387
continuing decline in prevalence, 387
current smoking prevention initiatives, 387–388
early twenty-first century, 387–388
educational level and, 387
eighteenth and nineteenth centuries, 385
electronic cigarettes, 387
government attempts to reduce, 385–386
growing awareness of the harms caused by smoking, 385–387
history of, 385–388
snuff, 385
socioeconomic status and, 387
tobacco companies’ awareness of tobacco toxicity, 386–387
tobacco industry denial of the addictive nature of nicotine, 386–387
twentieth century, 385–387
tolerance, 130, 553
alcohol, 319
barbiturates, 601
behavioral tolerance, 110, 115–116
conditioned tolerance, 116
conditioned tolerance to opioid drugs, 561–562
context-dependent tolerance, 230
context-specific effects, 148–149
definition of, 109
development in MDMA, 531–532
development of nicotine tolerance, 395–396
development with opioid drugs, 561–562
development with stimulant drugs, 509
difference between pleasurable and aversive drug effects, 134
metabolic tolerance, 110, 113–114
neuroadaptation and, 109–110
pharmacodynamic tolerance, 109–110, 130
receptor density changes in response to drugs, 109–110
role of receptors, 105
role of synaptic regulatory processes, 103
to the effects of THC in cannabis use, 449
types of, 110
Tour de France use of performance-enhancing stimulant drugs, 497
toxico logical tests diagnostic use, 61
Tracy, Sarah, 74
tranquilizer use disorders vignette ("Doctor Shopping for Xanax"), 594–595
tranquilizers benzodiazepines, 596–597, 601–612
development of, 596–597
misuse of, 597–598
tranquilizers (cont.)
prevalence of use and SUDs, 8–9
types of anxiolytic drugs, 595
transcription factors
activation by addictive
drugs, 155–156
CREB (cAMP response
element binding protein),
155–156
delta FosB, 156
transdermal route of entry for
drugs, 112
transgenic mice
nicotinic Ach receptors, 396
transition to SUDs
influence of personality
factors, 178–179
influence of
psychopathology, 178–179
treatment of SUDs
addiction as a treatable
condition, 626–627
Alcoholics Anonymous (AA)
approach, 628–629
cocaine addiction, 533–535
cognitive behavioral therapy
(CBT), 533
current state of addiction
treatment, 634
differences among addicted
individuals, 636–638
effectiveness of treatment,
672–674
evidence-based treatments,
634–635
history of addiction
treatment, 628–629
information and support
from the Internet and
social media, 632–633
many pathways out of SUD,
635
Matrix Model, 533–534
medical management of
withdrawal, 638
medical treatment for SUD,
638–639
methamphetamine addiction,
533–535
Minnesota Model, 629
motivations for stopping
versus continuing drug
use, 635–636
mutual assistance groups,
644–652
nonabstinent remission and
recovery, 669–672
popular culture accounts of
addiction treatment, 632
prevalence of SUDs in the
United States, 626
proposed improvements,
674–675
reasons for not seeking
treatment, 640–644
recovery, 635
reluctance to accept help or
stop using drugs, 627
remission, 635
similarities among addiction
treatments, 636
stimulant addiction,
533–535
theory-based approaches, 627
treatment philosophies, 627
treatment types and levels of
uptake, 626
treatment-relevant features
of SUDs, 635–640
twenty-first-century
approaches, 631–635
untreated remission of SUD,
640–644
use of medication as adjunct
treatment, 635
vignette (“The Almost-
Intervention”), 625–626
See also specific drugs
Trexan, 588
triazolam, 603
Tridimensional Personality
Questionnaire (TPQ), 278
Trotter, Thomas, 75
Twain, Mark, 668
TWEAK (tolerance, worried, eye-
opener, amnesia) test, 57
Tweak: Growing Up on
Methamphetamines
(Sheff), 11
twisting, 515
twelve-step facilitation therapy,
665
twelve-step programs, 11, 147,
219, 629, 645
character defects concept,
270
disease concept of addiction,
78, 79
evidence of effectiveness,
650
informal diagnosis of SUDs,
37
limited use of addiction
treatment medications,
376
Minnesota Model compared
with mental health
professional approaches,
629
motivating abstinence,
661–662
nonresidential treatment
programs, 655–656
office-based treatment,
652–653
proposed improvements,
674–675
psychotherapy, 657–662
relapse prevention, 668–669
residential treatment
programs, 654–655
transition to co-occurring
psychiatric disorders,
656–657
twelve-step facilitation therapy,
665
types of therapies used,
662–668
typical features of SUD
treatment programs, 656
variations in diagnostic
procedures, 653–654
See also specific drugs
Twain, Mark, 668
TWEAK (tolerance, worried, eye-
opener, amnesia) test, 57
Tweak: Growing Up on
Methamphetamines
(Sheff), 11
character defects concept,
270
disease concept of addiction,
78, 79
evidence of effectiveness,
650
informal diagnosis of SUDs,
37
limited use of addiction
treatment medications,
376
Minnesota Model compared
with mental health
professional approaches,
629
motivating abstinence,
661–662
nonresidential treatment
programs, 655–656
office-based treatment,
652–653
proposed improvements,
674–675
relapse prevention, 668–669
residential treatment
programs, 654–655
transition to co-occurring
psychiatric disorders,
656–657
see also specific drugs
Twain, Mark, 668
managing cravings, 244
mutual help approach, 628–629
nicotine addiction and, 429–430
online meetings, 632
risk factors for relapse, 149–150
role of narcissism in addiction, 274–275
terminology used in, 36
use of cognitive behavioral concepts, 234
See also Alcoholics Anonymous (AA)
twin studies
alcohol use disorders, 173–174
gene influence on SUDs, 172–175
nicotine use and dependence, 174
research approach, 172–173
Twitter, 633
University of Michigan, 21
untreated remission of SUDs, 640–644
vaccines against drug effects
potential for addiction treatment, 534–535
potential for development, 113
Vilain, George, 27, 79, 81–82, 83, 85, 343, 348, 351, 352, 356–357, 673
Valium, 9, 262, 314, 596, 602, 603, 606, 608, 610
protein binding in the bloodstream, 115
withdrawal syndrome, 114
vaping.
See electronic cigarettes
varenicline, 244, 431, 534, 635
ventral tegmental area role in SUDs, 126–129
ventromedial prefrontal cortex, 142
Versed, 603
Viagra, 515
Vicodin, 9, 509, 541, 551, 568
nonmedical use, 568
Viet Nam Era Twin Registry, 175
Vietnam conflict
heroin use among American military personnel, 545
violence associated with stimulant drug use, 519–520
Virginia Twin Registry, 175
Vivitrol, 316, 375, 588
Volkoff, Nora, 128, 220
Vivyanse, 489
Wechsler Adult Intelligence Scale-IV, 473
Wechsler Intelligence Scale for Children-Revised, 473
weight gain on stopping smoking, 400, 413
weight loss
use of amphetamine for, 489
Well, Andrew, 450
Wellbutrin, 431, 534
Wemicke-Korsakoff syndrome, 364–365
West, Robert, 27, 217, 299
White, William, 86, 90
whole-genome association tests, 203–204
willpower, 140
Wilson, Bill, 645
Winehouse, Amy, 5, 627
Wisconsin Inventory of Smoking Dependence Motives, 393–394
withdrawal syndrome.
alcohol, 317, 362–364
barbiturates, 601
benzodiazepine receptor agonists (BZRAs), 615–616
benzodiazepines, 611–612
chronic-pain patients on opioid therapy, 578
compansatory response and, 230
cocaine, 527–530
cannabis, 464–465
chronic-pain patients on opioid therapy, 578
cocaine, 527–530
neuroadaptation and, 109
conditioned withdrawal response, 149, 566–567
delirium tremens stage of alcohol withdrawal, 363–364
fat-sequestered drugs, 115
mechanism of, 110
medical management of withdrawal, 638
methamphetamine, 527–530
neonatal abstinence syndrome, 584–585
neuroadaptation and, 109
neurological substrates of acute and protracted withdrawal syndromes, 130–134
nicotine, 174, 395–397, 399–406
opioid drug addicts, 565–567
opioid drugs, 562–563–564
pharmacokinetics of drug elimination, 114
physiological withdrawal syndrome, 47–48
significance in defining addiction, 10–11
stress responses influence the hedonic set-point, 134
THC, 464–465
withdrawal from heavy stimulant use, 527–530
Z-drugs, 615–616
See also craving.
women
alcohol use disorders, 357–361
cultural influences and vulnerabilities to alcohol use disorders, 359–360
difficulty of detecting and diagnosing SUDs, 54
factors in lower success in stopping smoking, 412–413
fetal alcohol spectrum disorder, 372–374
gender-related risk factors for alcohol use disorders, 359–360
gender-specific differences in alcohol use disorders, 358–359
health risks of smoking, 385
hormonal factors in nicotine dependence, 413
hormonal influences on effects of stimulant drugs, 501
incidence of alcohol use disorders, 357
patterns and consequences of disordered alcohol use, 361
risk related to smoking and oral contraceptives, 422
risks of smoking during pregnancy, 422
sensitivity to MDMA, 530
Index

women (cont.)
smoking in women, 412–413
smoking-induced panic disorder, 408
special features of alcohol use disorders, 357–361
teratogenic effects of alcohol, 372–374
use of alcohol compared with men, 357
weight gain on stopping smoking, 413
Women for Sobriety (WFS), 645, 652
working memory

cognitive demands of craving, 242
World Health Organization (WHO), 308

alcoholism as a disease, 75
ICD system, 49
Wurtzel, Elizabeth, 507

Xanax, 48, 100, 108, 262, 333, 486, 509, 603, 606, 612
vignette ("Doctor Shopping for Xanax"), 594–595
withdrawal syndrome, 114, 115

Yale University Center for Alcohol Studies, 74
Young Adult Alcohol Problems Screening Test (YAAPST), 57

Z-drugs, 596–597, 612–617
abuse potential, 36

adverse effects, 616–617
bioavailability, 613–614
effects on brain function, 614
pharmacodynamics, 614
pharmacokinetics, 613–614
withdrawal syndrome, 615–616
zaleplon, 614
See also Z-drugs
Zofran, 356
Zoloft, 596
zolpidem, 598, 613, 614, 615–616–617
See also Z-drugs
zopiclone, 613, 614, 615, 616–617
See also Z-drugs
Zyban, 430–431